Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S. ...Middle East

PR Newswire - News
BEIJING, SHANGHAI and BOSTON, March 1, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C activator) from the...

Hence then, the article about jacobio pharma receives ind approval for p53 y220c activator jab 30300 in the u s was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S. )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News